ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
3,4,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3,5,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
4,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4,4,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
4,5,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
5,2,Teeth brittle,Dental disorders NEC,Dental and gingival conditions,Gastr,N
5,3,Tooth fracture,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
6,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
7,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
7,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
7,3,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
8,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
8,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
9,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
10,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
11,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
12,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
12,2,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
13,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
13,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
13,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
13,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
14,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
14,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
14,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
14,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
14,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
15,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
15,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
16,1,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
16,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
16,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
17,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
17,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
17,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
17,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
17,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
17,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
17,7,Myalgia,Muscle pains,Muscle disorders,Musc,N
17,8,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
19,1,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
20,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
20,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
20,3,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
20,4,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
20,5,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
21,1,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
22,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
22,2,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
23,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
24,1,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
25,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
25,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
26,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
26,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
26,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
26,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
26,5,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
26,6,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
26,7,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
26,8,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
26,9,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
26,10,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
26,11,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
26,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
27,1,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
27,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
27,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
28,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
28,2,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
29,1,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
29,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
30,1,Anal fistula,Gastrointestinal fistulae,Gastrointestinal conditions NEC,Gastr,N
30,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
31,1,Osteonecrosis of jaw,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
31,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
32,1,Iliac artery embolism,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
33,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
34,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
34,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
35,1,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
36,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
36,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
37,1,Osteonecrosis of jaw,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
38,1,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
38,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
39,1,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
39,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
40,1,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
40,2,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
41,1,Tracheal fistula,Tracheal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,Y
42,1,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
42,2,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
43,1,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
43,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
44,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
45,1,Tracheal fistula,Tracheal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,Y
46,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
46,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
46,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
47,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
47,2,Multimorbidity,General signs and symptoms NEC,General system disorders NEC,Genrl,N
47,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
48,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
48,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
48,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
48,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
48,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
48,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
48,7,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
48,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
48,9,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
48,10,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
48,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
49,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
49,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
49,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
50,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
51,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
52,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
53,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
54,1,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
55,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
55,2,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
56,1,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
57,1,Bell's palsy,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
58,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
58,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
58,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
58,4,Gastrointestinal perforation,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,Y
58,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
59,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
59,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
59,3,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
59,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
60,1,Abdominal sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
60,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
60,3,Cholangitis,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
60,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
60,5,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
60,6,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
60,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
60,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
60,9,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
60,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
61,1,Abdominal sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
61,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
61,3,Cholangitis,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
61,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
61,5,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
61,6,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
61,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
61,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
61,9,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
61,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
62,1,Anal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
62,2,Proctalgia,Anal and rectal pains,Anal and rectal conditions NEC,Gastr,N
63,1,Pneumothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
63,2,Pneumothorax spontaneous,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
64,1,Pneumothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
64,2,Pneumothorax spontaneous,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
65,1,Arteriovenous fistula site haemorrhage,Cardiac and vascular procedural complications,Procedural related injuries and complications NEC,Inj&P,N
66,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
66,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
66,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
66,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
66,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
66,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
66,7,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
66,8,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
66,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
66,10,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
66,11,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
66,12,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
67,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
68,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
69,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
70,1,Anal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
70,2,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,Y
70,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
71,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
72,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
72,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
73,1,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
73,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
73,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
74,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
74,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
75,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
76,1,Large intestine perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
77,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
77,2,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
77,3,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
77,4,Immune-mediated hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
78,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
78,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
78,3,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
78,4,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
78,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
79,1,Accelerated hypertension,Accelerated and malignant hypertension,Vascular hypertensive disorders,Vasc,N
80,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
81,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
81,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
81,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
81,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
81,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
81,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
81,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
81,8,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
81,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
82,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
83,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
83,2,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
83,3,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
83,4,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
84,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
84,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
85,1,Odynophagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
85,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
85,3,Tongue discomfort,Tongue signs and symptoms,Tongue conditions,Gastr,N
86,1,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
87,1,Cutaneous vasculitis,Skin vasculitides,Skin vascular abnormalities,Skin,N
87,2,Staphylococcal skin infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
88,1,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
89,1,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
90,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
90,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
91,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
91,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
92,1,Odynophagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
92,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
92,3,Tongue discomfort,Tongue signs and symptoms,Tongue conditions,Gastr,N
93,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
93,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
94,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
95,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
96,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
96,2,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
96,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
97,1,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
98,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
98,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
99,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
99,2,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
100,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
101,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
101,2,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
101,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
102,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
102,2,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
103,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
103,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
103,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
103,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
104,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
105,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
105,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
106,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
106,2,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
106,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
107,1,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
107,2,Spinal fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
108,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
108,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
108,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
108,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
108,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
109,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
109,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
110,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
111,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
112,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
112,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
112,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
112,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
113,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
113,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
113,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
113,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
113,5,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
114,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
115,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
115,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
116,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
116,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
116,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
116,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
117,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
118,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
119,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
119,2,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
120,1,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
120,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
121,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
121,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
122,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
123,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
123,2,Eosinophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
123,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
124,1,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
125,1,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
126,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
126,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
127,1,Diarrhoea infectious,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
127,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
127,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
127,4,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
128,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
129,1,Blister infected,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
129,2,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
130,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
130,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
130,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
130,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
131,1,Episcleritis,"Scleral infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
132,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
132,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
132,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
133,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
134,1,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
134,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
134,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
134,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
134,5,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
134,6,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
134,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
134,8,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
134,9,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
135,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
135,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
135,3,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
135,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
136,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
136,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
136,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
136,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
136,5,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
136,6,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
136,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
137,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
137,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
137,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
138,1,Appetite disorder,Appetite disorders,Appetite and general nutritional disorders,Metab,N
138,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
138,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
138,4,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
138,5,Metastases to soft tissue,Metastases to specified sites,Metastases,Neopl,N
138,6,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
138,7,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
138,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
139,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
139,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
140,1,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
140,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
141,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
142,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
142,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
142,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
142,4,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
143,1,Abdominal rigidity,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
143,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
144,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
144,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
145,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
145,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
145,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
146,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
146,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
147,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
147,2,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
147,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
147,4,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
147,5,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
147,6,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
148,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
149,1,Cardiac failure chronic,Heart failures NEC,Heart failures,Card,Y
149,2,Fibrin D dimer increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
149,3,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
149,4,Mitral valve incompetence,Mitral valvular disorders,Cardiac valve disorders,Card,N
150,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
151,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
151,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
151,3,Hypersomnia,Narcolepsy and hypersomnia,Sleep disturbances (incl subtypes),Nerv,N
151,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
152,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
152,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
152,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
152,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
153,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
153,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
154,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
155,1,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
156,1,Gastrointestinal perforation,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
157,1,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
157,2,Cytomegalovirus test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
157,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
157,4,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
157,5,Intervertebral disc protrusion,Intervertebral disc disorders NEC,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
157,6,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
157,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
157,8,Metastases to adrenals,Metastases to specified sites,Metastases,Neopl,N
157,9,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
157,10,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
157,11,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
157,12,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
157,13,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
157,14,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
157,15,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
157,16,Spinal osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
157,17,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
157,18,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
158,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
158,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
158,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
158,4,Immobile,Disability issues,Lifestyle issues,SocCi,N
159,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
159,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
160,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
161,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
161,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
162,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
162,2,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
163,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
163,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
163,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
163,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
163,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
164,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
164,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
164,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
164,4,Metastases to adrenals,Metastases to specified sites,Metastases,Neopl,N
165,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
165,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
165,3,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
165,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
166,1,Bell's palsy,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
167,1,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
167,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
167,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
167,4,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
167,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
167,6,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
168,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
168,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
168,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
169,1,Cancer pain,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
169,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
169,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
169,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
169,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
169,6,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
169,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
170,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
170,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
170,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
170,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
170,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
170,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
170,7,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
170,8,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
170,9,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
170,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
171,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
171,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
171,3,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
171,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
172,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
172,2,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,N
173,1,Cancer pain,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
173,2,Metastases to adrenals,Metastases to specified sites,Metastases,Neopl,N
173,3,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
173,4,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
173,5,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
173,6,Pleural disorder,Pleural conditions NEC,Pleural disorders,Resp,N
173,7,Postoperative wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
173,8,Wound dehiscence,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
174,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
174,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
174,3,Metastases to pelvis,Metastases to specified sites,Metastases,Neopl,N
174,4,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
175,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
175,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
175,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
175,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
176,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
176,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
176,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
177,1,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
177,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
177,3,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
178,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
178,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
178,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
179,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
180,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
181,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
181,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
181,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
181,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
182,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
182,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
182,3,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
183,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
183,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
184,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
185,1,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
186,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
186,2,Skin wound,Skin injuries NEC,Injuries NEC,Inj&P,N
187,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
187,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
187,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
187,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
187,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
188,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
188,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
188,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
188,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
188,5,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
189,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
189,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
190,1,Blood prolactin increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
190,2,Blood testosterone decreased,Reproductive hormone analyses,Endocrine investigations (incl sex hormones),Inv,N
190,3,Cortisol decreased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
190,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
190,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
190,6,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
190,7,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
190,8,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
190,9,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
190,10,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
190,11,Thyroxine free decreased,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
191,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
191,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
191,3,Blood calcium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
191,4,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
191,5,Hyperadrenocorticism,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
191,6,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
191,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
191,8,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
191,9,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
191,10,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
192,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
192,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
192,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
192,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
193,1,Cortisol decreased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
193,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
193,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
193,4,Headache,Headaches NEC,Headaches,Nerv,N
193,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
193,6,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
193,7,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
193,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
193,9,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
193,10,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
193,11,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
193,12,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
193,13,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
194,1,Acute abdomen,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
194,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
195,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
195,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
195,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
195,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
195,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
195,6,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
195,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
195,8,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
195,9,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
195,10,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
195,11,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
195,12,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
195,13,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
196,1,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
196,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
196,3,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
197,1,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
197,2,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
197,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
198,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
199,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
200,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
200,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
201,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
201,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
202,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
202,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
202,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
203,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
203,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
204,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
204,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
204,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
204,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
205,1,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
205,2,Pulmonary cavitation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
206,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
206,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
206,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
206,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
206,5,Tumour ulceration,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
207,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
207,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
207,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
208,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
209,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
209,2,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
209,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
209,4,Immune-mediated hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
209,5,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
209,6,Synovitis,Synovial disorders,Synovial and bursal disorders,Musc,N
210,1,Oesophageal stenosis,Oesophageal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
211,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
211,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
211,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
212,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
212,2,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
212,3,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
212,4,Post procedural fever,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
212,5,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
212,6,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
213,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
213,2,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
213,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
213,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
214,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
214,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
214,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
214,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
214,5,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
215,1,Aspiration,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
215,2,Chest wall tumour,Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas),Soft tissue neoplasms malignant and unspecified,Neopl,N
215,3,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
215,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
215,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
215,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
215,7,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
215,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
215,9,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
215,10,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
216,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
216,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
217,1,Pyoderma gangrenosum,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
218,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
218,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
218,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
218,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
218,5,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
218,6,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
218,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
219,1,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
220,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
221,1,Tongue discomfort,Tongue signs and symptoms,Tongue conditions,Gastr,N
222,1,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
223,1,Pyoderma gangrenosum,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
224,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
225,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
226,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
227,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
228,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
228,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
228,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
228,4,Death,Death and sudden death,Fatal outcomes,Genrl,Y
228,5,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
228,6,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
228,7,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
228,8,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
228,9,Lymphatic fistula,Lymphangiopathies,Lymphatic vessel disorders,Vasc,N
228,10,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
228,11,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
228,12,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
228,13,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
228,14,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
228,15,Post procedural complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
229,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
229,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
229,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
229,4,Metastases to stomach,Metastases to specified sites,Metastases,Neopl,N
229,5,Metastases to uterus,Metastases to specified sites,Metastases,Neopl,N
230,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
230,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
231,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
231,2,Blood magnesium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
231,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
231,4,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
231,5,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
231,6,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
232,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
232,2,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
233,1,Poor venous access,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
234,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
234,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
234,3,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
235,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
235,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
235,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
236,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
236,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
237,1,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
238,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
238,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
239,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
239,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
240,1,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
241,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
241,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
241,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
241,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
241,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
241,6,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
241,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
241,8,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
241,9,Myalgia,Muscle pains,Muscle disorders,Musc,N
241,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
241,11,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
241,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
241,13,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
241,14,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
241,15,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
242,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
243,1,Tongue discomfort,Tongue signs and symptoms,Tongue conditions,Gastr,N
244,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
244,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
244,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
244,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
244,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
245,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
246,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
246,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
246,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
246,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
247,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
247,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
248,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
249,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
249,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
249,3,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
249,4,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
250,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
250,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
250,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
250,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
251,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
251,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
251,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
252,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
252,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
252,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
252,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
252,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
252,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
253,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
253,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
253,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
253,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
254,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
254,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
254,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
254,4,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
254,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
254,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
254,7,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
254,8,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
254,9,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
254,10,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
254,11,Myalgia,Muscle pains,Muscle disorders,Musc,N
254,12,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
255,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
255,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
255,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
256,1,Excessive cerumen production,External ear disorders NEC,External ear disorders (excl congenital),Ear,N
257,1,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
257,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
257,3,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
257,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
258,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
258,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
258,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
258,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
259,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
259,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
260,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
260,2,Cholangitis,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
260,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
260,4,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
260,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
260,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
261,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
261,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
261,3,Large intestine perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
261,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
262,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
262,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
262,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
263,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
263,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
263,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
264,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
265,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
265,2,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
265,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
265,4,Vitiligo,Hypopigmentation disorders,Pigmentation disorders,Skin,N
266,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
266,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
266,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
266,4,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
266,5,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
266,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
267,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
267,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
267,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
268,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
268,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
268,3,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
268,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
269,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
270,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
270,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
270,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
270,4,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
270,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
270,6,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
270,7,Ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
270,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
271,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
272,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
272,2,Central nervous system lesion,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
272,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
273,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
273,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
273,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
274,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
274,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
274,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
275,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
275,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
276,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
276,2,Musculoskeletal disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
276,3,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
276,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
277,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
277,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
277,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
277,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
277,5,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
278,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
278,2,Central nervous system lesion,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
278,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
279,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
279,2,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
279,3,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
279,4,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
279,5,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
279,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
280,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
280,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
280,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
281,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
282,1,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
283,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
283,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
283,3,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
284,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
284,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
285,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
285,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
286,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
286,2,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
287,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
288,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
288,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
289,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
289,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
289,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
289,4,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
289,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
289,6,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
289,7,Ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
289,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
290,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
290,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
290,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
290,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
290,5,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
290,6,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
291,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
291,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
291,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
291,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
292,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
292,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
293,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
293,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
293,3,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
293,4,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
293,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
294,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
294,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
294,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
294,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
295,1,Change in seizure presentation,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
295,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
295,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
296,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
296,2,Clostridium difficile colitis,Clostridia infections,Bacterial infectious disorders,Infec,N
296,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
296,4,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
296,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
296,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
296,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
296,8,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
297,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
298,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
298,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
298,3,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
298,4,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
298,5,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
298,6,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
298,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
299,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
299,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
300,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
300,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
301,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
301,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
301,3,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
301,4,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
301,5,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
301,6,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
301,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
302,1,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
303,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
303,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
303,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
303,4,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
303,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
303,6,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
303,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
303,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
304,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
305,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
305,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
306,1,Cardiac dysfunction,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
306,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
306,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
307,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
307,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
307,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
307,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
307,5,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
307,6,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
307,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
307,8,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
307,9,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
307,10,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,Y
307,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
308,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
308,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
308,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
308,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
308,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
309,1,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
310,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
310,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
311,1,Hyperbilirubinaemia,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
311,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
311,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
312,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
312,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
312,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
312,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
313,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
313,2,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
313,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
313,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
314,1,Anal lesion excision,Anorectal therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
314,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
314,3,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
314,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
314,5,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
315,1,Bone cancer metastatic,Bone neoplasms malignant (excl sarcomas),Skeletal neoplasms malignant and unspecified,Neopl,N
315,2,Drug effect less than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
316,1,Drug effect less than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
316,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
317,1,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
318,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
318,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
318,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
319,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
320,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
320,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
320,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
320,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
320,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
320,6,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
321,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
321,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
321,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
321,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
321,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
321,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
321,7,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
322,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
322,2,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
323,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
323,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
324,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
324,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
324,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
324,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
324,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
325,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
325,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
326,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
327,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
327,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
328,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
328,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
329,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
329,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
329,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
329,4,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
329,5,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
329,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
330,1,Tumour necrosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
331,1,Tumour necrosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
332,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
333,1,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
334,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
334,2,Limb operation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
334,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
334,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
335,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
336,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
336,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
336,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
336,4,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
337,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
337,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
337,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
337,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
338,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
338,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
338,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
338,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
339,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
339,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
339,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
339,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
339,5,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
339,6,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
339,7,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
340,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
340,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
340,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
341,1,Alanine aminotransferase abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
341,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
341,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
342,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
342,2,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
343,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
344,1,Hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
344,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
